Search

Author/Creator Rudin, Charles M

1. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. (28th November 2018)

Authors:
Sabari, Joshua K; Offin, Michael; Stephens, Dennis; Ni, Andy; Lee, Adrian; Pavlakis, Nick; Clarke, Stephen; Diakos, Connie I; Datta, Sutirtha; Tandon, Nidhi; Martinez, Andres; Myers, Mackenzie L; Makhnin, Alex; Leger, Ysleni; Yu, Helena A; Paik, Paul K; Chaft, Jamie E; Kris, Mark G; Jeon, Jeong O...
Journal:
Journal of the National Cancer Institute
Issue:
Volume 111:Number 6(2019)
Page Start:
575
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Issue 12 (December 2016)

Authors:
Drilon, Alexander; Rekhtman, Natasha; Arcila, Maria; Wang, Lu; Ni, Andy; Albano, Melanie; Van Voorthuysen, Martine; Somwar, Romel; Smith, Roger S; Montecalvo, Joseph; Plodkowski, Andrew; Ginsberg, Michelle S; Riely, Gregory J; Rudin, Charles M; Ladanyi, Marc; Kris, Mark G
Journal:
Lancet oncology
Issue:
Volume 17:Issue 12(2016:Dec.)
Page Start:
1653
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Issue 1 (20th January 2023)

Authors:
Rudin, Charles M; Pandha, Hardev S; Zibelman, Matthew; Akerley, Wallace L; Harrington, Kevin J; Day, Daphne; Hill, Andrew G; O'Day, Steven J; Clay, Timothy D; Wright, Gavin M; Jennens, Ross R; Gerber, David E; Rosenberg, Jonathan E; Ralph, Christy; Campbell, David C; Curti, Brendan D; Merchan, Ja...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 11:Issue 1(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Issue 1 (January 2017)

Authors:
Rudin, Charles M; Pietanza, M Catherine; Bauer, Todd M; Ready, Neal; Morgensztern, Daniel; Glisson, Bonnie S; Byers, Lauren A; Johnson, Melissa L; Burris, Howard A; Robert, Francisco; Han, Tae H; Bheddah, Sheila; Theiss, Noah; Watson, Sky; Mathur, Deepan; Vennapusa, Bharathi; Zayed, Hany; Lally, ...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 1(2017:Jan.)
Page Start:
42
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗